A 62-year-old woman was admitted to our hospital with acute onset of left-sided hemiparesis. On admission, she had left-sided hemiplegia and facial palsy with minor dysarthria -National Institutes of Health Stroke Scale (NIHSS) 11. Cerebral computed tomography (CCT) and CT angiography demonstrated right MCA mainstem occlusion but no early ischemic changes. We initiated thrombolysis with rt-PA (0.9 mg/kg) 165 min after symptom onset. With this therapy, the patient improved to NIHSS 5.
Dresden , Germany
Case Report A 62-year-old woman was admitted to our hospital with acute onset of left-sided hemiparesis. On admission, she had left-sided hemiplegia and facial palsy with minor dysarthria -National Institutes of Health Stroke Scale (NIHSS) 11. Cerebral computed tomography (CCT) and CT angiography demonstrated right MCA mainstem occlusion but no early ischemic changes. We initiated thrombolysis with rt-PA (0.9 mg/kg) 165 min after symptom onset. With this therapy, the patient improved to NIHSS 5.
However, 1 h after termination of thrombolysis, she developed a sudden decline of consciousness. Since a repeat CCT ruled out intracranial hemorrhage (ICH), we suspected non-convulsive status epilepticus and gave intravenous lorazepam (6 mg) and valproic acid (bolus administration 900 mg, followed by 6-hour infusion 100 mg ؒ h -1 ). Electroencephalographic (EEG) monitoring was technically not feasible. The patient remained stuporous requiring intubation and mechanical ventilation the next morning. MRI demonstrated a new occlusion of the left MCA and the left internal carotid artery (ICA), as confi rmed by duplex ultrasound. The right MCA appeared recanalized ( fi g. 1 ). In the presence of only small DWI lesions, PI showed a perfusion defi cit of the complete left MCA territory resulting in a large PI/DWI mismatch. Therefore, we initiated treatment with intravenous abciximab (bolus administration 0.25 mg/kg, followed by 12-hour infusion therapy 0.125 g ؒ kg
) 17.5 h after onset of new symptoms. Duplex sonography performed after the abciximab infusion demonstrated persistent occlusion of the left ICA but recanalization of the left MCA. The patient initially remained comatous. Repeated CCTs on days 1, 3 and 5 after thrombolysis ruled out ICH or major ischemia. EEG ruled out seizure activity, and there was no evidence for metabolic coma. She subsequently regained consciousness and was extubated after 11 days.
Further workup revealed a stalked thrombus in the left atrial ear (transesophageal echocardiography) and intermittent atrial fi -
Introduction
Intravenous thrombolysis with alteplase (rt-PA) is the treatment of choice for ischemic stroke within 3 h of symptom onset [1] . Metaanalysis of the major thrombolytic stroke trials suggest a small, but still signifi cant, benefi t if given within 3-6 h [2] [3] [4] . Based on the results of a recent trial, the glycoprotein IIb/IIIa receptor antagonist abciximab may be a treatment option for this time window [5] .
Potentially viable penumbral tissue may be present well beyond 6 h, in isolated cases even up to 48 h [6] . Modern imaging techniques like magnetic resonance imaging (MRI) using diffusionweighted (DWI) and perfusion imaging (PI) may identify the penumbra and permit improved patient selection [7, 8] . Nevertheless, the best treatment for these patients has not yet been defi ned. This particularly applies to patients with recurrent or new symptoms after an initially successful thrombolysis where an early second thrombolytic therapy is debatable.
We report on a patient with acute left middle cerebral artery (MCA) occlusion occurring after thrombolysis with rt-PA for right MCA occlusion, whom we successfully treated with intravenous abciximab 17.5 h after onset of new symptoms. brillation (Holter ECG) strongly suggesting recurrent cardiac embolism. Therefore, we commenced secondary prophylaxis with subcutaneous low-molecular-weight heparin (nadroparin 0.7 ml/day) 2 days after thrombolysis with abciximab. An asymptomatic left temporo-occipital ICH seen on routine MRI 3 weeks after thrombolysis was rated as a complication of anticoagulation but did not result in therapeutic alterations.
Two months later, we saw the patient in our outpatient clinic. She had a minor right-sided hemiparesis and was independent without help (NIHSS 2, modifi ed Rankin Scale 1). The fi nal infarction volume corresponded to the DWI lesions on the initial MRI. The ICH had resolved completely ( fi g. 2 ). Subsequently, the patient was started on warfarin.
Discussion
In acute ischemic stroke, the identifi cation of an ischemic penumbra may result in a therapeutic dilemma, because treatment beyond 6 h after symptom onset has only been studied in a phase II study so far [9] . Nevertheless, the penumbra may be present for up to 48 h [4] , and consequently, thrombolytic therapy may be justifi ed.
The glycoprotein IIb/IIIa receptor anatagonist abciximab has been safely applied up to 24 h after the onset of ischemic stroke [10] . So far, abciximab has not proven its effi cacy, but showed a nonsignifi cant shift in favorable functional outcomes as measured by the modifi ed Rankin Scale score at 3 months (odds ratio 1.20; p = 0.33; 95% CI 0.84-1.70) [5] . Therefore, abciximab is expected to play a major role in future stroke therapy [11] .
In this case report, abciximab was applied 17.5 h after the onset of new symptoms following fi brinolysis with rt-PA for right-sided MCA occlusion. The long time lag until a diagnosis of recurrent stroke was reached was caused by initial misinterpretation of symptoms. Non-convulsive status epilepticus at stroke onset may have contributed to the clinical deterioration, but was not proven because EEG monitoring was technically not feasible. Several EEGs performed in the postacute phase showed no epileptic activity. Nevertheless, seizure at stroke onset should not be regarded as an absolute contraindication to thrombolysis in the presence of potentially salvageable tissue [12] .
The demonstration of left MCA occlusion and PI/DWI mismatch proved that recurrent stroke was the main reason for the secondary clinical deterioration of the patient. This situation was presumably caused by recurrent cardiac embolism. Few case reports outline the risk of rt-PA in the setting of myocardial infarction or ischemic stroke to break up or detach cardiac thrombotic material and promote recurrent embolism [13, 14] . This mechanism might also have been relevant in our patient. However, in a recent series of 5 stroke patients with a cardiac thrombus undergoing thrombolysis with rt-PA, there was no increased risk of recurrent embolism [15] .
Despite the prolonged time window and prior rt-PA treatment, therapy with abciximab was safe, because no ICH occurred. The ICH seen on MRI 3 weeks after thrombolysis was related to anticoagulation with low-molecular-weight heparin because it did not show on prior CCTs. Abciximab was also effective because the fi nal infarction volume corresponded to the initial DWI lesion, the occluded MCA was recanalized early, and the patient had a good clinical outcome.
In conclusion, therapy with abciximab can be a treatment option in selected patients even if given beyond 6 h after symptom onset and after prior thrombolysis with rt-PA. Fig. 2 . Repeat CCT performed 2 months after thrombolytic therapy shows infarctions in the basal ganglia bilaterally, in the left insular ribbon and the internal capsule, identical to the DWI lesions on initial MRI. The asymptomatic left temporo-occipital ICH seen on routine MRI 3 weeks after thrombolysis is completely resorbed.
